// App-Quantinova.ai

: A Phase1/1b Dose Escalation/Dose Expansion Study of Prgn-3007 Ultracar-T Cells in Patients with Advanced Hematologic and Solid Tumor Malignancies

Researchers

Presenter

  • Javier Pinilla Ibarz

Principal Investigators

  • Amy Lankford

  • Helen Sabzevari

  • Bijal D. Shah

  • Hatem Soliman

  • Julio C. Chavez

  • Rutul R Shah

Medical Centers

  • Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

  • Breast Oncology, Moffitt Cancer Center, Tampa, FL

  • Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL

  • Moffitt Cancer Center, Tampa, FL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B cell lymphomas

  • Solid malignancies

  • Lymphomas

  • Diffuse large B-cell lymphoma

  • Triple-negative breast cancer

Biomarkers

  • Breakpoint Cluster Region

  • Apparent diffusion coefficient

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

Outcome

  • N/A

Study Design

  • Safety

  • Adaptive

  • Expansion Study

  • Dose Escalation

  • Investigator Initiated

  • First-In-Human

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved